This Article Full Text Full Text (PDF) All Versions of this Article: 146/9/3999    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Komm, B. S. Articles by Lyttle, C. R. Search for Related Content PubMed PubMed Citation Articles by Komm, B. S. Articles by Lyttle, C. R.

Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity

Wyeth Research, Women’s Health Research Institute, Collegeville, Pennsylvania 19426

Address all correspondence and requests for reprints to: Barry Komm, 500 Arcola Road, Building N3252, Collegeville, Pennsylvania 19426. E-mail: kommb{at}wyeth.com.

We assessed the preclinical characteristics of a novel, stringently screened selective estrogen receptor modulator, bazedoxifene acetate, including its ability to bind to and activate estrogen receptors and promote increased bone mineral density and bone strength in rats, and the effects impacting the uterine endometrium, breast cancer cell proliferation, and central nervous system-associated vasomotor responses in an animal model. Bazedoxifene bound to estrogen receptor- with an IC₅₀ of 26 nM, an affinity similar to that of raloxifene. Bazedoxifene did not stimulate proliferation of MCF-7 cells but did inhibit 17ß-estradiol-induced proliferation with an IC₅₀ of 0.19 nM. In an immature rat uterine model, bazedoxifene (0.5 and 5.0 mg/kg) was associated with less increase in uterine wet weight than either ethinyl estradiol (10 µg/kg) or raloxifene (0.5 and 5.0 mg/kg). Histological analysis revealed that coadministration of bazedoxifene also appeared to reduce raloxifene-stimulated endometrial luminal epithelial cell and myometrial cell hypertrophy. In ovariectomized rats, bazedoxifene was associated with significant increases in bone mineral density at 6 wk, compared with control, and better compressive strength of bone samples from the L4 vertebrae, compared with samples from ovariectomized animals. In the morphine-addicted rat model of vasomotor activity, bone-sparing doses of bazedoxifene alone were not associated with 17ß-estradiol inhibition of increased vasomotor activity. Bazedoxifene acetate represents a promising new treatment for osteoporosis, with a potential for less uterine and vasomotor effects than selective estrogen receptor modulators currently used in clinical practice. Controlled clinical trial data will be needed to confirm these effects.

This article has been cited by other articles:

				S. Y. Dai, M. J. Chalmers, J. Bruning, K. S. Bramlett, H. E. Osborne, C. Montrose-Rafizadeh, R. J. Barr, Y. Wang, M. Wang, T. P. Burris, et al. Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method PNAS, May 20, 2008; 105(20): 7171 - 7176. [Abstract] [Full Text] [PDF]

				A. L Stump, K. W Kelley, and T. M Wensel Bazedoxifene: A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis Ann. Pharmacother., May 1, 2007; 41(5): 833 - 839. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				R. P. A. Barros, U. F. Machado, M. Warner, and J.-A. Gustafsson Muscle GLUT4 regulation by estrogen receptors ERbeta and ER{alpha} PNAS, January 31, 2006; 103(5): 1605 - 1608. [Abstract] [Full Text] [PDF]